Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 6 recruiting now early-phase tilt small index

Prostate Cancer Metastatic Disease: early-phase trial registry

6 of 6 indexed Prostate Cancer Metastatic Disease trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · 6 currently recruiting · #2,866 of 28,707 conditions by registered trial count

Prostate Cancer Metastatic Disease: 6 US clinical trials tracked, 6 recruiting.

Prostate Cancer Metastatic Disease is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Shehzad Basaria, M.D., running 1 of these trials.

Enrollment posture brief

Registry condition prostate-cancer-metastatic-disease

OPEN 6 | RECR 100% | LATE 0 | EARLY 4 | RANK #2866 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Prostate Cancer Metastat (th…100%Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leukemia50%
Open-enrollment share among volume-matched conditions near Prostate Cancer Metastatic Disease

Prostate Cancer Metastatic Disease lists 6 open slots (100% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Prostate Cancer Metastatic Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Prostate Cancer Metastatic Disease is recruiting above its size-band peers.

    6 of 6 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Prostate Cancer Metastatic Disease research.

    Shehzad Basaria, M.D. accounts for 1 of 6 trials (16.7%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Most Prostate Cancer Metastatic Disease trials plan to enrol fewer than 100 people.

    Median target enrolment is 60 among the 6 trials that report a genuine target (sentinel values excluded). 6 of those (100%) plan for fewer than 100 participants.

  4. Prostate Cancer Metastatic Disease research is mostly interventional.

    6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 23

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 3

Named interventions

Most-linked intervention names on Prostate Cancer Metastatic Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

fezolinetant - reference formulation Drug
1 trials
0.06mg/kg ZOPOCIANINE given days prior to surgery Drug
1 trials
0.03mg/kg ZOPOCIANINE given day prior to surgery Drug
1 trials
0.06mg/kg ZOPOCIANINE given day of surgery Drug
1 trials
0.03mg/kg ZOPOCIANINE given day of surgery Drug
1 trials
Positron Emission Tomography (PET) Procedure
1 trials
FAPI Radiation
1 trials
Hypocaloric anti-inflammatory diet Behavioral
1 trials

US sites by state

Facility locations filed on Prostate Cancer Metastatic Disease trials. A trial with sites in several states counts in each.

Massachusetts 2 trials
Wisconsin 1 trials
Texas 1 trials
Tennessee 1 trials
South Carolina 1 trials
New York 1 trials
Michigan 1 trials
Indiana 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Prostate Cancer Metastatic Disease page

6 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 6 Prostate Cancer Metastatic Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Shehzad Basaria, M.D. sponsors the most Prostate Cancer Metastatic Disease trials on record, review their full trial history before evaluating a specific study. See Shehzad Basaria, M.D.'s trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Prostate Cancer Metastatic Disease condition card totals 6 registered trials; most-linked intervention fezolinetant - reference formulation; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.